268 related articles for article (PubMed ID: 27018569)
1. Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.
Münch J; Avanesov M; Bannas P; Säring D; Krämer E; Mearini G; Carrier L; Suling A; Lund G; Patten M
J Card Fail; 2016 Oct; 22(10):845-50. PubMed ID: 27018569
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
Green JJ; Berger JS; Kramer CM; Salerno M
JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
[TBL] [Abstract][Full Text] [Related]
4. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
[TBL] [Abstract][Full Text] [Related]
6. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
[TBL] [Abstract][Full Text] [Related]
8. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
[TBL] [Abstract][Full Text] [Related]
9. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Yang C; Qiao S; Song Y; Liu Y; Tang Y; Deng L; Yuan J; Hu F; Yang W
Cardiovasc Pathol; 2019; 43():107150. PubMed ID: 31639652
[TBL] [Abstract][Full Text] [Related]
10. Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
Elmas E; Doesch C; Fluechter S; Freundt M; Weiss C; Lang S; Kälsch T; Haghi D; Papassotiriou J; Kunde J; Schoenberg SO; Borggrefe M; Papavassiliu T
Int J Cardiovasc Imaging; 2011 Apr; 27(4):547-56. PubMed ID: 20872251
[TBL] [Abstract][Full Text] [Related]
11. Myocardial collagen turnover in hypertrophic cardiomyopathy.
Lombardi R; Betocchi S; Losi MA; Tocchetti CG; Aversa M; Miranda M; D'Alessandro G; Cacace A; Ciampi Q; Chiariello M
Circulation; 2003 Sep; 108(12):1455-60. PubMed ID: 12952838
[TBL] [Abstract][Full Text] [Related]
12. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy.
Perazzolo Marra M; De Lazzari M; Zorzi A; Migliore F; Zilio F; Calore C; Vettor G; Tona F; Tarantini G; Cacciavillani L; Corbetti F; Giorgi B; Miotto D; Thiene G; Basso C; Iliceto S; Corrado D
Heart Rhythm; 2014 May; 11(5):856-63. PubMed ID: 24440822
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy.
Ellims AH; Taylor AJ; Mariani JA; Ling LH; Iles LM; Maeder MT; Kaye DM
Circ Heart Fail; 2014 Mar; 7(2):271-8. PubMed ID: 24481111
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
He D; Ye M; Zhang L; Jiang B
Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
[TBL] [Abstract][Full Text] [Related]
15. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
[TBL] [Abstract][Full Text] [Related]
16. Matrix Metalloproteinases Increase Because of Hypoperfusion in Obstructive Hypertrophic Cardiomyopathy.
Bi X; Yang C; Song Y; Yuan J; Cui J; Hu F; Qiao S
Ann Thorac Surg; 2021 Mar; 111(3):915-922. PubMed ID: 32738221
[TBL] [Abstract][Full Text] [Related]
17. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
[TBL] [Abstract][Full Text] [Related]
18. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
[TBL] [Abstract][Full Text] [Related]
19. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
[TBL] [Abstract][Full Text] [Related]
20. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis.
Briasoulis A; Mallikethi-Reddy S; Palla M; Alesh I; Afonso L
Heart; 2015 Sep; 101(17):1406-11. PubMed ID: 26060120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
